Publish Date: September 2019
Ethiopia is among countries with high maternal mortality, with severe pre-eclampsia/eclampsia being one of the leading direct causes. If women receive effective care delivered according to evidence-based standards, the majority of deaths related to pre-eclampsia/eclampsia could be avoided. The management of severe pre-eclampsia/eclampsia, including controlling severe hypertension, through the correct use of magnesium sulfate and anti-hypertensive drugs, respectively, can significantly reduce complications and deaths related to severe pre-eclampsia/eclampsia. However, the use of magnesium sulfate was only recently adopted in Ethiopia in 2010 and it is still not widely used.
This study aimed to determine if an active audit and feedback intervention in public referral hospitals in Ethiopia improves the quality of care (i.e., increased and appropriate use of magnesium sulfate and anti-hypertensive therapy) provided to women who experience either pre-eclampsia/eclampsia or a hypertensive crisis.
Active Audit and Feedback Intervention to Increase Use of Magnesium Sulfate and Anti-Hypertensive Therapy among Women with Severe Pre-eclampsia and Eclampsia in Public Referral Hospitals in Ethiopia (840 downloads)